Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04456998 · ClinicalTrials.gov registry record · Phase 2
GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
A Phase 2 study, sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT04456998 is a Phase 2 study that has completed, run by GB002, Inc., a wholly owned subsidiary of Gossamer Bio. The registered enrollment target is 86 participants.
The verdict
NCT04456998, a Phase 2 study, has completed, sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
The primary objective for this trial is to determine the effect of GB002 (seralutinib) on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III. The secondary objective for this trial is to determine the effect of GB002 (seralutinib) on improving exercise capacity in this population.
Interventions
- DRUG Placebo
- DRUG GB002 (seralutinib)
- DEVICE Generic Dry Powder Inhaler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2020-11-12 |
| Est. Completion | 2022-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04456998
The ClinicalTrials.gov registry entry for NCT04456998 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GB002, Inc., a wholly owned subsidiary of Gossamer Bio, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04456998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04456998 about?
NCT04456998 is a clinical study titled "GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)". The primary objective for this trial is to determine the effect of GB002 (seralutinib) on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III. The secondary objective for this trial is to determine the effect of GB002...
What is the current status of trial NCT04456998?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2020-11-12. Estimated completion is 2022-11-01.
What interventions are being tested in trial NCT04456998?
The interventions under investigation include: Placebo (DRUG), GB002 (seralutinib) (DRUG), Generic Dry Powder Inhaler (DEVICE).
Who is sponsoring clinical trial NCT04456998?
This trial is sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.